# Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C

> **NCT00038649** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 117 (actual)

## Conditions studied

- Myelogenous Leukemia, Chronic, Chronic Phase

## Interventions

- **DRUG:** Gleevec

## Key facts

- **NCT ID:** NCT00038649
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-06
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 117 (ACTUAL)
- **Why stopped:** Sponsor discontinued providing study drug.
- **Last updated:** 2018-10-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00038649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00038649, "Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00038649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*